David J. Friedman, M.D., Ph.D
Assistant Professor of Medicine
Beth Israel Deaconess Medical Center
Harvard Medical School
330 Brookline Avenue, RN-227B
Boston, MA 02215
Office Phone: 617-667-0253
David Friedman graduated from Harvard College and received his medical degree from the Yale School of Medicine. He completed internal medicine residency and renal fellowship at BIDMC. He joined the CVBR in 2008. He is currently an Assistant Professor of Medicine at Harvard Medical School and an attending physician (nephrology) at BIDMC.
Research Interests: Renovascular Disease
Basic Research - My laboratory studies 1) genetic causes of chronic kidney disease; 2) the microvasculature in kidney disease; 3) diabetic nephropathy; and 4) the role of innate immunity and evolution in susceptibility to chronic kidney disease. We use human genetic studies combined with mouse models and molecular biology to understand these disease processes. One major project focuses on the role of APOL1 and the APOL gene family in causing kidney disease in African Americans. Our second focus is on genetic susceptibility to Mesoamerican Nephropathy, an unexplained epidemic of kidney disease in Nicaragua, El Salvador, and other countries in Central America.
New and Noteworthy Publications:
Friedman DJ, Rennke H, Csizmadia E, Enjyoji K, and Robson SC. "The Vascular Ectonucleotidase ENTPD1 is a Novel Renoprotective Factor in Diabetic Nephropathy." (2007) Diabetes 56(9): 2371-9.
Friedman DJ, Talbert ME, Bowden DW, Freedman BI, Mukanya Y, Enjyoji K, Robson SC.. "Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease." (2009) Diabetes. 58(4):999-1006.
Genovese G,* Friedman DJ,* Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Knob AU, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR. “Association of Trypanolytic ApoL1 Variants with Kidney Disease in African-Americans.” (2010) Science. 13;329(5993):841-5.
Friedman DJ, Pollak MR. “Genetics of kidney failure and the evolving story of APOL1.” (2011) J Clin Invest. 121(9):3367-74.
Thomson R, Genovese G, Canon C, Kovacsics D, Higgins MK, Carrington M, Winkler CA, Kopp J, Rotimi C, Adeyemo A, Doumatey A, Ayodo G, Alper SL, Pollak MR, Friedman DJ,* Raper J.*. “Evolution of the Primate Trypanolytic Factor APOL1.” PNAS 2014 May 20;111(20):E2130-9.